Nymox Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Nymox Pharmaceutical has been growing earnings at an average annual rate of 12.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 82.6% per year.
Key information
12.6%
Earnings growth rate
20.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -82.6% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Nymox gets FDA feedback on NDA resubmission for lead asset
Sep 13Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Aug 17NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq
Jul 14Nymox to file for Fexapotide approval by mid-September
May 06Nymox under pressure on $8M private placement
Apr 28What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition
Mar 01Revenue & Expenses BreakdownBeta
How Nymox Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | -5 | 2 | 0 |
30 Jun 23 | 0 | -5 | 2 | 0 |
31 Mar 23 | 0 | -3 | 3 | 0 |
31 Dec 22 | 0 | -7 | 3 | 4 |
30 Sep 22 | 0 | -8 | 4 | 7 |
30 Jun 22 | 0 | -10 | 5 | 8 |
31 Mar 22 | 0 | -15 | 6 | 10 |
31 Dec 21 | 0 | -13 | 6 | 7 |
30 Sep 21 | 0 | -12 | 5 | 7 |
30 Jun 21 | 0 | -13 | 5 | 8 |
31 Mar 21 | 0 | -12 | 4 | 8 |
31 Dec 20 | 0 | -12 | 4 | 8 |
30 Sep 20 | 0 | -12 | 4 | 9 |
30 Jun 20 | 0 | -11 | 4 | 7 |
31 Mar 20 | 0 | -13 | 6 | 7 |
31 Dec 19 | 0 | -13 | 6 | 7 |
30 Sep 19 | 0 | -13 | 6 | 7 |
30 Jun 19 | 0 | -14 | 6 | 7 |
31 Mar 19 | 0 | -11 | 5 | 6 |
31 Dec 18 | 0 | -11 | 4 | 7 |
30 Sep 18 | 0 | -11 | 4 | 7 |
30 Jun 18 | 0 | -13 | 5 | 8 |
31 Mar 18 | 0 | -13 | 5 | 8 |
31 Dec 17 | 0 | -13 | 5 | 8 |
30 Sep 17 | 0 | -13 | 6 | 7 |
30 Jun 17 | 0 | -11 | 4 | 7 |
31 Mar 17 | 0 | -13 | 6 | 7 |
31 Dec 16 | 0 | -13 | 6 | 7 |
30 Sep 16 | 0 | -14 | 7 | 8 |
30 Jun 16 | 0 | -21 | 10 | 11 |
31 Mar 16 | 0 | -23 | 13 | 10 |
31 Dec 15 | 3 | -18 | 12 | 9 |
30 Sep 15 | 3 | -14 | 11 | 7 |
30 Jun 15 | 4 | -5 | 6 | 3 |
31 Mar 15 | 5 | 0 | 2 | 3 |
31 Dec 14 | 3 | -5 | 3 | 4 |
30 Sep 14 | 3 | -5 | 3 | 5 |
30 Jun 14 | 3 | -6 | 3 | 6 |
31 Mar 14 | 3 | -6 | 3 | 6 |
31 Dec 13 | 3 | -5 | 2 | 6 |
30 Sep 13 | 3 | -6 | 2 | 7 |
30 Jun 13 | 3 | -7 | 2 | 8 |
Quality Earnings: NYMX.F is currently unprofitable.
Growing Profit Margin: NYMX.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NYMX.F is unprofitable, but has reduced losses over the past 5 years at a rate of 12.6% per year.
Accelerating Growth: Unable to compare NYMX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYMX.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: NYMX.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.